# Taiwan Universe BioMedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/taiwan-universe-biomedicine

- Headquarters: Taiwan - China
- Website: www.taiutw.com
- Total disclosed funding: $2M
- Latest round: Seed (Aug 1, 2025)
- Investors on record: 2

## About

Taiwan Universe BioMedicine Inc., based in Taiwan, is a biotechnology company focused on developing advanced vaccines targeting critical health challenges such as enteroviruses and influenza strains.Founded in 2024 in Taiwan, Taiwan Universe BioMedicine Inc. specializes in vaccine development. The company received USD 2.000 mn in SEED funding on August 1, 2025, led by Mosaic Venture Lab and supported by National Development Fund. Dr. Min-Shi Lee, the founder, brings a wealth of experience in biotechnology, contributing to the firm's innovative approach in addressing global health issues.TaiU, a biotechnology start-up founded by Dr. Min-Shi Lee, specializes in the development of advanced vaccines, specifically bivalent enterovirus vaccines and seasonal influenza virus-like particle (VLP) vaccines. Utilizing innovative technology platforms, the company aims to address critical health challenges posed by enteroviruses and influenza strains, including emerging viral threats. The production process for these vaccines leverages insect cell systems, specifically Sf21 and Hi5, resulting in a scalable and efficient manufacturing capability. TaiU targets healthcare providers, government public health agencies, and research institutions as its primary customer base, focusing on markets in North America, Europe, and Asia where there is a pressing need for effective vaccine solutions. The company is positioned to contribute significantly to global public health by providing timely and adaptable vaccine options for both seasonal and novel influenza viruses.TaiU’s revenue model is structured around B2B transactions, focusing on partnerships with healthcare organizations, government entities, and academic institutions. The company engages in direct sales of its vaccine products or establishes collaborative agreements for research and development. Revenue streams include the sale of individual vaccine doses or bulk purchases aimed at public health initiatives. Furthermore, TaiU explores licensing agreements to allow other manufacturers to utilize its proprietary technology in vaccine production, with revenue generation contingent on successful regulatory approvals and market establishment.In August 2025, Taiwan Universe BioMedicine Inc. raised USD 2.000 mn in SEED funding, which will be allocated to support continuous clinical trials based on vaccinations. The company is focused on developing new vaccine products to enhance its portfolio. It also plans to expand its presence in North America, Europe, and Asia, targeting specific markets where the demand for effective vaccine solutions is growing. The recent funding will accelerate their research and development efforts to bring these new products to market.

## Funding rounds

- Seed, Aug 1, 2025, $2M — National Development Fund, Mosaic Venture Lab

## Investors

- National Development Fund (https://capitalatlas.ai/funds/national-development-fund) — Seed
- Mosaic Venture Lab (https://capitalatlas.ai/funds/mosaic-venture-lab) — Seed